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Abstract: “How do drugs cross the plasma membrane?” this may seem like a trivial question. This question is often over-
looked to focus primarily on the different complex macro-molecular aspects involved in drug delivery or drug resistance. 
However, recent studies have highlighted the theme that to be fully understood, more knowledge of the underlying biol-
ogy of the most complex biological processes involved in the delivery and resistance to drugs is needed. After all, why 
would a drug interact with a transporter then subsequently be excluded from P-glycoprotein (P-gp) expressing drug resis-
tant cells? What are the determinants of this transition in behavior? Full consideration of the physical biology of drug de-
livery has allowed a better understanding of the reasons why specific membrane proteins are upregulated or overexpressed 
in drug resistant cells. This, in turn, allows us to identify new targets for drug chemicals. Better yet, it increases the sig-
nificance of recents patents and underlines their importance in multi drug resistance.  
Keyword: Cell membrane, drug delivery, drug resistance, pharmacokinetics, physical biology. 
INTRODUCTION  
 Most of the antitumor agents commonly used in cancer 
treatment clinics induce their effect by targeting DNA repli-
cation, cell division and related mechanisms. These strate-
gies, which are directly aimed at the core of the proliferation 
process, have led to widely-used antineoplastic treatments to 
date. Despite positive impact in clinics, these treatments bear 
intrinsic limitations that in some cases are slowing the pace 
of therapeutic progress and prompt us to explore new con-
cepts such as those discussed by our colleagues in this spe-
cial issue. These limitations pertain to the intracellular mode 
of action of the drugs, the complex and heterogeneous nature 
of the tumorigenic process, and the multiplicity of causes 
that can lead to drug resistance [1]. In several cases, it has 
even been proposed that this can be responsible for the fact 
that some therapies can even exacerbate the original malig-
nant phenotype, induce suppression of apoptosis, and in fine 
improve the progression of the disease [1-3].  
 All of the drugs that are aimed at intracellular targets 
have to undergo common molecular processes that trigger 
their partition between the extracellular medium, the bilayer 
membrane, and the cytoplasm. Therefore, understanding 
how these drugs can penetrate, accumulate or can be ex-
cluded from normal and cancer cells constitutes one of the 
areas worthy of investigation to optimize classical antitumor  
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treatments, decrease side effects and to better understand 
drug resistance. This process is summarized in Fig. (1), 
which shows that three important parameters have to be 
thoroughly taken into account: (i) membrane properties: 
packing, charge, potential, and composition, (ii) physico-
chemical parameters of the drugs: size, hydrophobicity, net 
charge, pKas of the protonable groups, and (iii) properties of 
intracellular spaces: pH, potential, intracellular compart-
ments. In this case, the membrane properties interact with 
drugs to block their transverse diffusion thereby increasing 
their ability to diffuse laterally in the membrane (we shall 
see that this will increase the probability of drug and drug 
transporter interactions). However, even when drugs traverse 
the plasma membrane, alterations in cytosolic and vesicular 
pH can be enough to trap the drug in specific compartments. 
 In this review, instead of focusing on new and non-
genomic approaches to cancer treatment, which are very well 
described in other articles, we will revisit the basic principles 
that govern drug uptake by cells, i.e. accumulation and ex-
trusion. Furthermore, instead of reviewing all drug or mem-
brane complex physico-chemical parameters involved in 
drug delivery, we shall focus our attention on the role of 
drug size, membrane mechanical properties - i.e. membrane 
endocytosis - and, finally, on cytosolic pH. The reason for 
this specific focus is renewed interest in the role of the 
plasma membrane’s basic biophysical properties. This will 
lead us to discuss the above-mentioned parameters, and the 
action of PgP-like proteins that have been thought to func-
tion as efflux pumps, as well as the importance of acidic in-
tracellular compartments in the sequestration of protonatable 
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drugs. By taking into account the principles of membrane 
physical chemistry and drug diffusion in a different context, 
this review will highlight important points that may lead to 
the design of optimized treatments or better adjunct therapy 
strategies. 
HISTORICAL CONNECTION BETWEEN FLUID 
PHASE ENDOCYTOSIS AND MEMBRANE PHYSICS: 
IMPLICATION FOR DRUGS UPTAKE.  
 In the introduction, the term endocytosis was associated 
with the mechanical properties of the plasma membrane. 
This relationship is central to the understanding of how and 
why the size of a drug is paramount to determine the mode 
of delivery. For that reason, it is important to start this re-
view with a few paragraphs explaining how, historically, this 
connection was made possible. 
 Fluid phase endocytosis has puzzled scientists for a rela-
tively long time. The reason for this is that membrane vesi-
cles created this way do not require a protein coat, contrary 
to clathrin coated pits. Accordingly, the motor force re-
mained elusive until it was connected to membrane lipid 
asymmetry. To introduce how endocytosis is related to the 
differential packing of lipids, let’s consider first a vesicle as 
is found in living cells Fig. (2A). Once formed, membrane 
vesicles have a radius of about R ~ 50nm and as the vesicle 
radius is only ten fold higher than the membrane thickness 
(h ~ 5nm) , R / h ~10 , it is quick to see that the surface area 
of the outer leaflet is larger than the surface area of the inner 
leaflet Fig. (2A). Thus, the outer leaflet of a vesicle must 
have significantly more lipid than the inner leaflet. Assum-
ing that lipids have a cross sectional area 0~ a , the differ-
ence in lipid number between the outer and inner leaflets 
( N ) is given by a0  N ~ Sout  Sin , where Sout  Sin  is the 
difference between the outer and inner surface area. As this 
difference is also given by Sout  Sin ~ S0 h / R , where S0  is 
defined as the neutral surface area of the vesicle (see Fig. 
(2A)). According to the equations above, it follows that the 
vesicle radius is, geometrically speaking, inversely propor-
tional to the lipid number asymmetry between leaflets 
R ~1/ N , reviewed in [4]. As the outer leaflet of the vesicle 
comes from the inner leaflet of the membrane, this result 
suggests that for a vesicle to be created, more lipids have to 
be stored in the inner leaflet of the cell membrane, relative to 
the outer leaflet. This feature has been linked to the way the 
membrane organize their own lipid composition. 
 It is well known that lipids are not randomly distributed 
in the cell membrane, but follow a strict composition be-
tween leaflets thanks to a specific lipid enzyme flippase [5]. 
For example, phosphatidylserine and phosphatidylethanola-
mine are maintained in the inner leaflet, and actively relo-
cated from the outer to the inner leaflet if needed, by a lipid 
flippase [6, 7]. The connection between the asymmetry in 
phospholipid composition of the cell membrane and endocy-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Summary of the different mechanisms that determine the distribution of a drug from the extracellular side to the membrane space 
and to the cytoplasm. 
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tosis, including the cell membrane mechanical properties, 
came in three phases.  
 First, in well defined model systems it was found that the 
shape of giant unilamellar liposomes (GUVs) described by 
physical parameters like the global curvature, could be al-
tered by changing the lipid asymmetry between leaflets [8] 
and that, conversely, by providing an adequate theory based 
on the mechanical properties of such biomembrane systems 
(known as the “area-difference elasticity” (ADE) model) it 
was possible to predict the changes in the GUV’s shape as a 
function of the lipid asymmetry imposed [9]. This first phase 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). (A) Lipid asymmetry at the vesicular scale: Given the small size of vesicles, the radius and membrane thickness are relatively close 
together ( R / h ~10 ). Thus, the outer leaflet of a vesicle ( Sout ) has significantly more lipid than the inner leaflet ( Sin ). As the vesicle is 
spherical, noting S0 = 4R2  the neutral surface area namely the surface area between the outer and inner leaflets, it follows at the first order 
that Sout = 4 (R + h / 2)2 ~ S0 (1+ h / R)  and Sin = 4 (R  h / 2)2 ~ S0 (1 h / R) . Thus Sout  Sin ~ S0 h / R . (B) Sketch representing the current 
model linking fluid phase endocytosis to the membrane phospholipid number asymmetry [6]. In the left panel, the translocation of dark-
headed lipids into the inner leaflet induces a differential packing of lipids between leaflets leading to membrane bending and vesiculation 
[11, 12]. Note that the membrane recycling that occurs in cells (right panel), i.e. the exocytosis of vesicles with a size similar to endocytic 
vesicles, allows the maintenance of the lipid asymmetry and thus the maintenance of the differential packing of leaflets at the level of the 
plasmalemma. The relationship existing between the lipid number asymmetry and the vesicle radius is given by R = 8kc / hK (N / N0 ) . Ac-
cordingly, the lipid number asymmetry has been experimentally deduced from studies on drug sensitive cells (K562) with a value 
N / N0 = 4%  providing a ~35 nm vesicle radius [12]. Note that as the mechanisms of endocytosis and exocytosis are symmetrical to one 
another, there is no need to pump lipid into the inner leaflet in a continuous way. Indeed, endocytosis and exocytosis taken together ensure a 
contant lipid asymmetry and constant membrane recycling. This phenomenon is known a dynamical instability in physics[26]. (C) Represen-
tation of the different energy barriers (noted together U(x) ) and involved when a drug traverses the bilayer cellular membrane. Two leaflets 
represent the membrane with an inner leaflet containing more phospholipids related to the increase in the difference in surface tensions (up-
per graph). Energy profiles of lipid packing in both leaflet (plain curve-lower graph) and hydrophobic core of membrane (dashed curve-
lower graph) are both involved in providing penalty energies with regard to the transbilayer movement of drugs. As the inner leaflet is 
packed, drugs crossing the membrane will be trapped in this leaflet which will delay and impair their flow into the cytosol . The latter effect 
will be dependent on the size of drugs as bigger drugs will “feel more strongly” this mechanical barrier. In the present paper, this effect is 
supposed to be central for the high levels of cross resistance to drugs that Biedler and Riehm measured.  
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allowed the connection between membrane shapes and 
membrane mechanical properties. Secondly, the relationship 
between the lipid asymmetry and endocytosis came when it 
was discovered that imposing a sufficient lipid asymmetry in 
GUVs produced membrane budding [8], this experiment was 
repeated in cells and it was found that an excess of phos-
phatidylserine added in the inner leaflet, namely translocated 
from the outer into the inner leaflet by a flippase activity [6, 
10], increases the kinetic of endocytosis [11]. Thirdly, from 
the connection between living and model systems, it was 
proposed a theory of endocytosis inspired from the ADE 
model [4, 12]. This theory suggests that to generate endocy-
tosis, namely an inward membrane budding, a constant lipid 
number asymmetry is needed at the level of the cell mem-
brane, maintained by the flippase activity and the membrane 
recycling Fig. (2B). The underlying physical formulas are 
given in appendix.  
 This model was compared to experimental analysis and it 
was deduced that there exists a lipid number asymmetry in 
the membrane of eukaryotic cells: N / N0 ~ 4% , where 0N  
corresponds to the average number of lipid in either leaflet 
(see appendix) [12]. This theory provides a vesicle radius of 
~35nm similar to what is observed and measured in living 
cells. Therefore, this model suggests that endocytosis results 
from a differential packing of lipids between the inner and 
outer leaflets of the cell membrane Fig. (2C). Note that it is 
not because the model focuses on phospholipids that it does 
rule out the involvement of cholesterol. Since cholesterol 
partions equally between leaflets, it is not involved in the 
membrane asymmetry. Regarding the role of lipid rafts, 
since these are rigid patches, the lipid asymmetry theory 
does not apply; (they have unique biophysical properties) 
[13, 14].  
 The role of the differential packing on drugs’ membrane 
permeability can now be addressed. The membrane barrier 
potential, namely the energy required for a drug to cross the 
membrane, is a complex function of the set of interactions 
between a drug and the membrane components, which varies 
along the membrane thickness. Initially, drugs are expected 
to insert the outer leaflet by optimizing their energy (i.e. 
chemical potential). Thus, the hydrophobic (non polar) part 
of the drug is presumed to be present in the hydrophobic 
core of the membrane. Resulting from this assumption is the 
fact that to incorporate totally the inner leaflet and to traverse 
the bilayer, the drug must transfer its hydrophilic (polar) part 
in the hydrophobic core (i.e. oily phase) of the membrane. 
This process corresponds to the dehydration of the drug. This 
will inevitably lead to a penalty energy that usually prevails 
in the middle of the membrane (dashed curve in Fig. (2C)), 
and that shall be noted: Ehydra = G . Note however that this 
penalty energy will remain constant when a cell switches its 
state from drug sensitivity to resistant, as it is related to the 
physico-chemical properties of the drug. 
 Finally, to pass through the membrane the drug will also 
have to bypass the barrier energy linked to the differential 
packing of lipids. This penalty energy is maximal at the level 
of polar heads, where the repulsion between lipids dominates 
(plain curve in Fig. (2C)). As a result, large drugs will feel 
the packing more strongly because they are more 
“squeezed”. It can be demonstrated that this energy is: 
a K  N / N0 , where a  is the cross section area of the drug 
intercalated in the membrane, K  the elastic modulus of the 
membrane and “ N / N0 ” the lipid asymmetry (see appen-
dix). Note that contrary to the former penalty energy, the 
lipid packing is expected to be increased in the drug resistant 
state, given the higher kinetic rates of endocytosis measured 
in drug resistant cells, see [15-17] and references within. In 
addition, given that the spatial dimension of the drug is in-
volved (i.e. “ a ”), this means that the size of the drug, or 
equivalently its molecular weight (MW), is central. Provid-
ing that the lipid packing difference is related to the fluid 
phase vesicle radius, the mechanical energy a K  N / N0  
can be rewritten as:  
Emech = a
8kc
hR
 (1) 
Where 
c
k  is the bending modulus of the membrane (see 
appendix). Contrary to the lipid asymmetry that has not been 
measured directly in living systems, the later relation diplay 
more amenable variables including membrane thickness, 
vesicle radius and membrane bending modulus that can be 
measured directly. With Eq.1, the impact of membrane lipid 
asymmetry on drugs size exclusion can be, at least in theory, 
studied.  
THE CRITICAL PARAMETERS THAT GOVERN 
DRUG DIFFUSION ACROSS MEMBRANES  
 One thing that comes directly from the above equation is 
that because large drugs have difficulty to cross the mem-
brane, they will remain in the membrane for longer. This 
point is clearly indicated by the measure of diffusion coeffi-
cients of drugs in biomembranes. Indeed, classical anticancer 
drugs have a relatively small apparent diffusion coefficient 
through biomembranes ~10-6μm2/s [18]. In water however, 
the same coefficient is ~102μm2/s [19, 20], which gives a 
ratio in the diffusion coefficients of eight orders of magni-
tude. Such a difference is explained by the intrinsic energy 
needed for a drug to traverse the membrane.  
 Finally, using Arrhenius’s Law, the residency time of 
drugs in the membrane can be written explicitly to demon-
strate that it will be influenced by the biophysical properties 
we have dealt with from the start, namely dehydration and 
membrane mechanics: 
t0 ~ e
Ehydra+Emecha
kBT = e
G
kBT
+8
kca
kBThR
  (2) 
kB is Boltzmann’s constant and T  the absolute temperature. 
From Eq.2, it follows that the time required for the transbi-
layer movement of drugs is, now, exponentially dependent of 
of the drug cross sectional area in membrane. Noticeably, 
this enables to define a critical value for the drug cross sec-
tional area (ac) which yields an important connexion between 
membrane biophysics and drug size that will be later para-
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mount to understand multi drug resistance (MDR). Noting 
ac = hRkBT / 8kc . If a > ac = hRkBT / 8kc , the exponential func-
tion will be numerically high, meaning that in other words 
the difference in lipid packing will impair the drug transbi-
layer movement (the drug will stay in the membrane for 
longer). A numerical value of 
c
a  can be determined: con-
sidering a membrane thickness h ~ 5nm , a vesicle radius 
R ~ 35nm  determined for drug sensitive cells [12] and a 
membrane bending modulus, kc ~ 2.10
19 J  [21], it follows 
ac ~ 0.4nm
2  at 37ºC (Figure 3A). Assuming legitimately that 
the MW of the drug is proportional to its Van der Waals vol-
ume (expressed in  A3 ), a critical MW can also be deduced 
MWc = (4 / 3  )(hRkBT / 8kc )3/2 ~ 240  Fig. (3B), providing a 
law with regard to the drug size (or MW) selectivity on its 
permeation across the cell membrane. As a result it can be 
expected that modifications of lipid packing may produce 
resistance or sensitivity, depending whether the mechanical 
packing is amplified or diminished. 
 It is worth noting that the local membrane budding which 
leads to membrane vesiculation and controls the kinetics of 
endocytosis has been associated with an endogenous higher 
compression of the cellular membrane inner leaflet [11, 12, 
22, 23]. Therefore, another concept that can be derived from 
the previous equations is that modifications of membrane 
lipid packing that retroact on drug permeation also affect the 
radius of fluid phase endocytosis, which constitutes an easy 
readout for inner leaflet packing. Accordingly, changes have 
been noted regarding the cellular membrane of MDR cells. 
In particular, higher rates of endocytosis have been measured 
[24, 25]. As the kinetics of endocytosis is inversely propor-
tional to vesicle radius [26], it follows that the mechanical 
interaction between a drug and the membrane can be re-
written as: 8kca / hRkBT = (MW /MWc )
2/3  k / k0 . Thus Eq.2 can 
be rewritten as: 
 t0 ~ e
G
kBT
+
MW
MWc




2/3
 k
k0
 (3) 
where 0k  and k  are the rate of endocytosis when cells are 
sensitive (subscript “0”) and resistant to drugs respectively. 
Note that as endocytosis and exocytosis are symetrical to one 
another (see legend Fig. (2B)) and thus, changes in the cellu-
lar volume is not an option. If we assume that the membrane 
barrier energy will prolong the turnover time of the drugs 
that have partitioned in the membrane, they are expected to 
diffuse laterally, which may in turn increase the probability 
that they bind to and are extruded by a Pgp-like transporter. 
 So far we have determined how the time of residence of 
drugs in the cell membrane is determined by a complex mo-
lecular dialog between the drugs features and the membrane 
physical properties. We will now add a level of complexity 
by discussing how these factors are determining the interac-
tion with drug transporters. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). (A) Relationship existing between the drugs’ Van der 
Waals radius, 
 
rc ( A)  and their ability to bypass the membrane bar-
rier as a function of vesicular radius, R(nm)  (i.e. function of the 
difference in surface tension), scaling as rc ~ R
1/2 [exactly: 
rc  0.6 R1/2 ]. (B) The existing relationship between the MW of 
drugs and their ability to bypass the membrane barrier as a function 
of vesicles radius R(nm) , scaling as 
 
MW
c
~ r
c
3 ~ R3/2  [exactly: 
 
MW
c
= 4r
c
3 / 3 1.1 R3/2 ].  
MULTIDRUG RESISTANCE AND PGP-LIKE 
TRANSPORTERS 
 Let us assume a homogeneous lipid bilayer membrane. 
Pgp-like transporters are integral plasma membrane proteins 
that have been presumed to impair the intracellular accumu-
lation of drugs by extruding them at a rapid rate from the 
plasma membrane inner leaflet, before they reach the cytosol 
[27-37]. It follows that the efficiency of Pgp-like transporters 
to mediate MDR should rely on the rates of lateral diffusion 
of drugs from their initial incorporation in plasma mem-
branes to the transporters prior to extrusion. The longer the 
lateral path of diffusion before a drug is released into the  
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cytoplasm, the higher the probability of a drug binding to a 
transporter. Taken together, these different aspects point to 
the need to add supplementary dimensions to the “vacuum 
cleaner” model in which PgP functions as simple efflux 
pumps in a 2 dimensional membrane system. We will now 
address them by exploring additional factors related to the 
membrane physical properties. We will see that in this proc-
ess we may have to take into account a supplementary set of 
parameters: intracellular and extracellular pH. 
When Drugs Meet Pgp 
 Let us assume that: (i) the number of Pgps on the cellular 
surface of MDR cells remains globally constant so that the 
surface density, Pgp , is also constant (where 
Pgp = NPgpSPgp / Scell  with NPgp , SPgp  and Scell  representing the 
number of transporters, the cross section area of transporters and 
the cellular surface, respectively); (ii) the lateral diffusion time 
of integral plasma membrane Pgp-like transporters can be 
considered negligible when compared to the lateral diffusion 
time of much smaller drugs; and (iii) the probability of two 
drugs interacting with a given transporter at the same time is 
negligible. 
 Let us consider the lateral diffusion path noted: L . The 
spatial extent of the lateral diffusion is linked to the resi-
dency time of the drug in the membrane, given by Eq.3. 
More explicitely, as the diffusion takes place, the lateral 
membrane surface area visited by the drug is: L2 ~ Dt0 . Us-
ing the surface density of transporters, under these conditions 
it is possible to demonstrate that the probability of the event “drug 
meeting a Pgp” in the membrane, 
Pgp
p , is [38]: 
 pPgp ~ PgpL2    (4) 
 However, coming into contact with a Pgp is not enough 
and Pgp-mediated drug extrusion requires the location of the 
drug in the inner leaflet of the plasma membrane. Eq.4 has to 
be corrected for this. It can be demonstrated that the prob-
ability that a drug enters the inner leaflet can be approached 
by Maxwell-Boltzmann’s distribution, written as: 
TkG
Be
/
. 
As Pgp molecules and drugs have a low specificity toward 
one another and that lipophilic drugs have a better tendency 
to interact with Pgps, one can assume that when entering the 
inner leaflet and meeting a transporter a drug is extruded. In 
these conditions, the probability, 
 
pPgp , that a drug is effec-
tively expelled from the membrane by a transporter becomes 
finally: 
 
pPgp  e
 G
kBT pPgp . From the later equation, it follows 
that a membrane-embedded drug will inevitably meet a drug 
transporter only if 
 
pPgp = 1 . With this condition and by using 
Eq.4, it is thus possible to determine the critical surface den-
sity of transporters Pgpc  to generate MDR through the vac-
uum cleaner mechanism: 
Pgpc ~ e
 k
k0
 MW
MWc



	
2/3
 (5) 
 It is worth noting that when the mechanical effect be-
comes dominant, namely when the drug MW is large 
(MW>240) or when the kinetics of endocytosis is steadily 
increased as cells become resistant to drugs, then the surface 
density of Pgp-like transporters needed to trigger drug resis-
tance is predicted to be low. Doxorubicin with a MW of 545 
can be used as an example. Assuming that the kinetics of 
endocytosis is increased 4-fold in the MDR state (which re-
mains a realistic value in MDR, reviewed in [24, 39, 40]), it 
follows that the surface density of Pgp required would only 
represent a small fraction ~0.1-1% of the cellular surface 
area [15]. This means that as the inner leaflet packing in-
creases, the number of Pgp transporter potentially needed 
that will encounter and extrude drugs can decrease in an ex-
ponential way. Thus, paradoxically, if the main activity of 
Pgp is to handle drugs, then most of them are expected to be 
functionally ineffective in MDR. 
 Finally Eq.5 agrees at least in principle with seminal 
studies demonstrating that drug size is important in MDR 
[41-44]. MDR assays measure the effective dose (ED), de-
fined as the ability of drugs to kill 50% of a cell population 
(that is related to drug influx). EDs can be determined theo-
retically. The ability of any classical drug to kill a cell is 
dependent on its ability to cross the membrane. In this con-
text, providing that we know the probability that a drug is 
not extruded by Pgp, i.e. 
 
1 pPgp , and the drug residency time 
within the membrane, 0t , it is possible to demonstrate that 
the ratio between the effective doses (EDs) in the sensitive 
and resistant states can be written as: 
 
ln ED
MDR
/ ED
nonMDR( )  MW / MWc( )
2/3 
k / k
0
1( ) ln 1 
Pgp
/ 
Pgp
c( )
 (6) 
 Eq.6 shows that although the inhibition of the transmem-
brane flow of drugs going into the cellular cytoplasm can be 
performed through the expression of Pgp-like transporters, 
i.e. when Pgp = Pgpc , the transmembrane flow of drugs can 
also be reduced exponentially as a function of the kinetics of 
endocytosis. Furthermore, it emerges a universal power law 
(i.e. 2/3) that describes the drug/membrane mechanical inter-
action, and is directly related to the MW of the drug used. 
Eq.6 demonstrates that if the theory presented here is correct, 
then the ability of drugs to cross the cell membrane should 
follow a power law as a function of their MW. Thus, it 
should be possible to test the validity of the theory proposed. 
Indeed, Fig. (4) shows a very good correlation between the 
neperian logarithm of the lethal doses ratio and that of the 
molecular weigth of a set of anticancer drugs.  
 So far, we focused on basic membrane biophysical prop-
erties and found out their importance in MDR. Another im-
portant variable is the cytosolic pH also aletered when cells 
switch their state from sensitive to resistant. We will see in 
the next that an interaction between cytosolic pH and mem-
brane mechanics is also possible, hence explaining part of 
MDR.  
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WHY IS pH IMPORTANT?  
The Proton Paradox in Cancer Cells  
 Regardless of their origin and genetic background, cancer 
cells and tissues have been found to diplay an abnormality 
called “proton reversal” which consists in an interstitial acid 
microenvironment secondary to an initial, specific and 
etiopathogenic intracellular alkalosis [45-49]. Inasmuch, a 
failure to induce intracellular acidification has been proposed 
to be the main factor underlying drug resistance, and includ-
ing resistance to the induction of therapeutic apoptosis, in 
both highly alkaline cancer cells and in malignant cells with 
a normal or slightly elevated intracellular pH (pHi) [50-54]. 
First, a slightly alkaline pH has be envisioned as a permis-
sive factor for growth and, in second, anticancer drugs that 
are weak cations will be less protonated and therefore less 
retained in the intracellular spaces at a more alkaline pHi 
[54-65]. To exemplify these points, one of the most repre-
sentative and seminal findings in this area has been the ob-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). (A) Drug resistance levels mediated by drugs’ molecular weight. Eq.6 explains MDR when both drug properties (MW and dehydra-
tion energy) and transporter surface density are fixed. When cross resistance to drugs is considered the surface density of transporters may 
not be adequate to expel another drug with different physical properties. This scenario would be true if a smaller drug (i.e. low MW) than the 
one used to select the resistant phenotype is used, as it would cross the membrane more easily, which would decrease the probability of inter-
action between a drug and a transporter. At constant P-gp expression Eq.6 predicts that the influx of drugs into the cytosol would be chiefly 
dependent the MW/volume of drugs. The role of drug sizes involved in MDR was initially discovered in 1970 [41]. The authors generated a 
resistant cell line by selective incubation with actinomycin D (MW=1255) for several months, which led to expression of Pgp transporters. 
As a second step, they measured cross resistance levels using several other drugs (MW<1255). They measured how both resistant and sensi-
tive cell lines would respond to various drugs. Eq.6 predicts: 
 
ln ED
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/ ED
nonMDR( ) ~ MW / MWc( )
2/3  k / k
0
1( ) . The numerical data from 
Bielder and Riehm’s study are plotted in (A). (B) Power law of cross resistance to drugs. In order to determine whether a power law involv-
ing the MW exists, a double Neperian logarithm was applied to Bielder and Riehm’s data and it was found that, indeed, a power law 
~0.59±0.11 (b=0.59, plain curve) can be determined, which is similar to the one suggested by the drug/membrane mechanical interaction 
~0.66 (2/3~0.66) (b=2/3, dashed curve) (B). 
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servation that pH alkalization from an intracellular pH (pHi) 
of 7.0 to pHi 7.4 triggers a ~2000-fold increase in adriamycin 
resistance in human lung cancer cells [66]. This level of re-
sistance can be reversed by cellular acidification via admini-
stration of verapamil [66]. In parallel studies, the intracellu-
lar concentration of adriamycin was shown to be increased 
by more than 100-fold after inducing cellular acidification 
[67].  
 The relations between extrusion pumps and pH are more 
controversial. Several authors have shown that PgP might 
itself work as an ATP-dependent proton transporter, while 
others reported that pH changes, either extracellular or intra-
cellular, have no significant effect on drug extrusion by P-
glycoprotein [68-70].  
 Because inner leaflet lipids bear protonatable polar 
heads, pH changes will modify their net charge. In turn this 
will impact the sum of electrostatic repulsions and modify 
membrane tension. Based on the previous considerations we 
will now explore whether, in addition to its other effects, 
intracellular pH might also influence drug membrane per-
meation through modifications of membrane packing and 
tension.  
Cytosolic pH and lipid packing 
 To consider any effect of the pHi on lipid packing, it is 
central to understand the notion of packing from a physics 
standpoint. At a constant membrane surface area, the lipid 
packing is given by the optimal area per lipid in the cell 
membrane. The latter is deduced from the balance between 
repulsions that occur mostly through electrostatic effects on 
the polar heads, and attractions, which concern more the 
hydrophobic and geometric effects that take place between 
the aliphatic chain(s). Any changes in this balance are ex-
pected to affect the optimal area per lipid (i.e. their packing) 
and membrane shape. As a non negligible fraction of the 
inner leaflet consists in negatively charged lipids, such as 
phosphatidylserine or PIP2, for example [71] and that these 
lipids might also be organized in clusters, a slight increase in 
proton concentration around neutrality (e.g. decrease in pHi) 
will eliminate or shield these negative charges and decrease 
the electrostatic repulsion between polar groups. Although 
such an electrostatic counterion effect might be in principle 
generalized to intracellular cations, it is obvious that ex-
changeable protons will have a more pronounced effect on 
negatively charged lipids. As a final result, a low pHi is more 
likely to be central in abolishing the physical repulsion be-
tween lipids, and thus decreases the surface tension (i.e. the 
lipid packing of the cytosolic leaflet - note that both lipid 
packing and surface tension are proportional to each other). 
Such a relationship between free electrolytes and the cross 
section area per lipid in model biomembranes is well known 
experimentally [72-74]. Conversely, when the cytosolic pH 
increases (i.e. when cells become resistant to drugs in our 
case), fewer positive charges will be available to mask the 
lipids charge, which in turn is expected to increase their re-
pulsions and thus their packing. Thus, this higher lipid pack-
ing would increase the surface tension of the leaflet in con-
tact with the milieu of elevated cellular pH in the case of 
drug resistant cells. So, if the pH affects the packing of lip-
ids, and the packing of lipids affects the intracellular accu-
mulation of drugs, it follows that the cytosolic pH should 
affect the intracellular accumulation of those drugs. As a 
result, the changes in pHi observed when cells switch their 
state of resistance may be an important clue for understand-
ing the observed alterations of intracellular accumulation of 
drugs as a function of their sizes. In due course, this could 
provide a strong argument for the unification of the fields of 
drug bioavailability and drug resistance. As the packing of 
lipids is involved, we may expect that the endocytosis kinetic 
will also be affected by pHi.  
 In these conditions, it is possible to demonstrate that if 
the pH is involved, then the ratio between effective doses in 
MDR and non-MDR states should be written as follows [16]: 
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Where  pH = pHMDR  pHnonMDR is the cytosolic pH difference 
between the MDR and non MDR states, and   1.5  is a 
physical constant. The effect of Pgp mediated drug extrusion 
will be dominant only if Pgp ~ Pgpc  (in which case the Nepe-
rian logarithm becomes infinite). Note however that when 
the EDs are determined, the amount of drug added to cells is 
necessarily higher than the concentration of the same drug in 
culture condition and that is used to maintain the resistant 
phenotype. Therefore, full drug resistance is never reached 
when the effective doses are determined. It means therefore 
that when the effective doses are determined: Pgp < Pgpc  and 
that in the last term can be omitted. Eq.7 can be plotted 
against experimental data issued from different studies. Ac-
cordingly, it is possible to demonstrate the correlation be-
tween Eq.7 and the experimental data obtained with doxoru-
bicin Fig. (5A). This strongly suggests that effectively, the 
lethal doses are clearly dependant on cytosolic pH, as pre-
dicted in our model. 
Drugs in Vesicles: Keeping the Poisons Safely Inside  
 If drugs are blocked at the level of the membrane because 
of an excessive lipid packing (due to higher cytosolic pH) 
then, drugs will follow membrane endocytosis. As a result, 
drugs will flow into single membrane organelles. This point 
is central as it can be related to the role of drug pKa in MDR 
and acidic luminal pH of organelles.  
 Despite proving to be a useful simplification, considering 
a mammalian cell as a finite volume surrounded by a single 
lipid bilayer might be too reductionist to provide with an 
adequate depiction of drug cellular distribution. Indeed, a 
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large part of the eukaryotic cytoplasm is occupied by single-
membrane organelles, including Golgi apparatus, early and 
late endosomes, secretory vesicles, lysosomes that have spe-
cific characteristics including an acidic luminal pH which is 
crucial for fulfilling their cellular functions. Maintaining a 
low pH in the compartments of the secretory pathway is nec-
essary for posttranslational protein-modifications and sorting 
of newly synthesized proteins and lipids through packaging 
and processing of secretory vesicles to their final desti-
nations [75-77]. Likewise, keeping optimal pH through the 
endocytic pathway is essential for receptor-mediated 
endocytosis and directing internalized molecules towards 
either recycling or degradation [75, 78-81]. 
 The optimal pH in organelles is regulated by the balance 
between active H+ pumping and passive H+ efflux. Vacuolar 
proton-translocating ATPase (V-ATPase) has a central role 
in active pumping of protons and generating acidic luminal 
pH. Since V-ATPase is electrogenic, the translocation of 
positive charge (H+) in lumen generates a large membrane 
potential which can lead to inhibition of the enzyme’s further 
activity. Also, in some organelles V-ATPase activity can be 
interfered by presence of other transporters and channels that 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). (A) Comparison between experimental (blanked circles) doxorubicin resistance levels obtained in cells and the theory (filled circles) 
with N / N0 = 2%  (note that this value concerning the lipid asymmetry was determined previously [12]). The open circles corresponding 
to SW1573 (lung derived cancer cells), K562R (leukemic cancer cells) and MCF-7R (breast derived cancer cells) are indicated with arrows 
and labels. Finally the straight line is the linear regression of experimental data which agrees very well with the theory. (B) Effect of pH 
changes (cytosolic alkalization) on the surface density of Pgp transporters needed to trigger drug resistance. As seen in the figure the number 
of Pgp can decrease exponentially when the pH increases: the membrane takes over. 
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increase the membrane potential (such as Na+-K+ -ATPases 
in early endosomes). This can also have a negative influence 
on achieving desired pH [82-85]. On the contrary, the 
counterion current is responsible for shunting voltage in 
organelles and therefore allowing proper V-ATPase activity. 
This current is primarily mediated by chloride channels in-
cluding members of the CLC family and possibily the CFTR 
channel (cystic fibrosis transmembrane conductance regula-
tor) [86-90].  
 The existence of this steady-state pH reflects a ratio be-
tween H+ influx and H+ efflux, which indicates that proton 
leak is another important factor in maintaining organellar 
homeostasis. Several candidates for this leak have been pro-
posed. These include voltage-gated proton channels, [91, 
92], anion exchangers that can facilitate the intake of hy-
droxyl or bicarbonate ions, or members of the NHE family 
(Na+-H+ exchanger). The progressive decrease of pH in the 
secretory and endocytic pathways is achieved by the gradual 
increase of the V-ATPase density and at the same time de-
crease of the vesicular H+ permeability [93].  
 Interestingly, it has been shown that in transformed cells 
the existence of an acidic cytoplasm is coupled to an abnor-
mally alkaline organellar pH [94]. For instance, the ras-
transformed fibroblasts show significantly higher pH in 
lysosomes compared to the nontransformed parental cells 
[95]. This provides with an important clue to explain the 
greater sensitivity of cancer cells to antineoplastic agents 
when compared to normal cells, which makes the treatments 
possible in patients. In normal cells, these weak base drugs 
(pKs of 7-8) are sequestered by acidified organelles, while 
cells that have a higher organellar pH, are not able to 
sequester them as well, and are therefore more sensitive. 
Interestingly, drug-resistant tumor cells have restored organ-
ellar pH, and like normal cells can significantly reduce the 
accumulation of chemotherapeutic drugs in the cytosol and 
nucleus compared to drug-sensitive cells [94]. Because 
sequestration of protonable drug is a complex partition 
mechanism, it appears that the pH between cytosol and intra-
cellular compartments actually regulates cytosolic levels of 
chemotherapeutics and thus their level of cytotoxicity. For 
example, MCF-7 breast cancer cells have a decreased pH 
gradient due to the abnormal acidification of organelles, as 
well as the fragmentation and dispersion of the TGN (Trans 
Golgi Network) and endosomes throughout the cells [96, 
97]. On the contrary, the adriamycin-resistant cell line de-
rived from MCF-7 exhibits normal organelle acidification 
and distribution, and also adriamycin accumulation in acidic 
organelles which is unlikely for drug-sensitive MCF-7 cells. 
However, the disruption of vesicular acidification achieved 
by treatments with ionophores (nigericin and monensin) or 
with V-ATPase inhibitors (bafilomycin A1 and concanamy-
cin A), induces their resensitization to adriamycin [24]. This 
correlation between defects in organelles acidification and 
cells drug-sensitivity has also been confirmed in the study 
with tamoxifen. It has been reported that tamoxifen is able to 
resensitize drug-resistant tumor cells to other chemothera-
peutic drugs. It selectively alkalinizes acidified organelles 
without altering cytoplasmic pH and thus causes redistribu-
tion of weak base chemotherapeutics from organelles to the 
nucleus [24].  
CURRENT & FUTURE DEVELOPMENTS: 
 In this review, we have summarized how drug molecular 
properties, membrane mechanics, drug transporters, and the 
pH of cytosol and of intracellular compartments interact to-
gether to participate in uptake and extrusion of anticancer 
drugs in cells. In particular, we have tried to focus on three 
important points: firstly quantitative law of drug distribution 
based on this set of parameters can be established and fit 
well with data from the literature. Secondly, proton concen-
tration exerts a pleiotropic effect on anticancer drug sensitiv-
ity, by acting on drug ionization, on membrane tension and 
by setting the pH of cellular and subcellular compartments 
through pump and leak transporters. Thirdly, based on the 
previous elements, it is easy to understand why the pumping 
out of anticancer drugs from the cell in drug resistance, if 
alone, would be relatively marginal compared to these mul-
tiple effects of pH on the membrane. Although other more 
complex biological mechanisms involved in drug resistance, 
e.g. anti-apoptotic stimuli linked to cytosolic alkalization 
[98] might take place, and are certainly not ruled out, the 
different assumptions presented in this manuscript are sup-
ported by experimental evidence. Conversely, it is easily 
understandable that targeting the plasma membrane, pH 
regulation or intracellular compartments to eliminate tumor 
cells is of course not by itself sufficient but might potentiate 
existing treatments. Finally, as drugs used in multiple dis-
eases bear an important hydrophobic part and/or have to act 
on intracellular targets, it is important to point out that the 
different concepts highlighted in this review article are rele-
vant in a broader context than cancer chemotherapy. 
 Finally, it is worth noting that although drug chemicals 
targeting pH regulators/ions channels or transporters exist 
[99], nothing has been done to determine whether the mem-
brane mechanical properties can be targeted by drugs and 
thus manipulated. Although lipids or cholesterol sequestra-
tion/differential synthesis or metabolism [100, 101] might be 
a solution to overcome the membrane packing problem and 
MDR, the problem remains, today, entirely open and is in 
need of complementary investigations.  
IMPORTANCE OF RECENT PATENTS FOR THE 
PHYSICAL BIOLOGY OF DRUG RESISTANCE: 
 What has been underlined so far is that change in cytoso-
lic pH is central to driving drug resistance. It follows that 
every inventions, methods, techniques and design to reverse 
the cytosolic pH [102] should be emphasized. In particular, 
new chemicals acting on sodium -proton exchanger (NHE) 
[103, 104], ATP synthase [105-107] or the proton-linked 
monocarboxylate transporter (MCT) [108] could be used to 
prevent or reverse MDR. Selectivity would be achieved us-
ing the MCT inhibitors, since these transporters are found in 
a wide variety tumor cells and tissues, but much less so in 
normal tissues [109, 110]. For the MCT, two inhibitors have 
been discovered by AstraZeneca, which are active in the 
344    Recent Patents on Anti-Cancer Drug Discovery, 2011, Vol. 6, No. 3 Milosavljevic et al. 
nanomolar range. Preliminary data using one of these, com-
pound 8, indicates it does indeed have a pronounced effect 
on pHi, in experiments using neuroblastoma cells (data not 
shown). In addition, the NHE is far more active in an acidic 
microenvironments, which is what you have in the tumor 
microenvironment [111]. Since it is expected that any inhibi-
tors of these transporters may cause upregulation of non-
inhibited transporters, ultimately a cocktail (mixture) of in-
hibitors may be necessary to maintain the anti-tumor effect. 
The best NHE inhibitor available, already used clinically for 
other applications in the UK, is cariporide [112].  
 An additional transporter, ATP synthase, was first identi-
fied by the Pizzo research group [113, 114]. This transporter 
is found on endothelial cells in the tumor microenvironment 
and on tumor cells themselves. It is oriented such that ATP is 
generated on the outer surface of cells. This transporter is 
inhibited by angiostatin, but when angiostatin was tried 
clinically, it was found to be cleared from the circulation 
with a half-life of less than 15 minutes. A suitable more sta-
ble inhibitor of this transporter is reservatrol (Wahl, unpub-
lished observations). This ingredient of red grapes and red 
wine is currently being touted in the United States as an anti-
aging remedy. In experiements measuring intracellular pH in 
live cells, it behaved exactly like angiostatin, bringing about 
an intracellular pH decrease when coupled with acute ex-
tracellular acidification in tumor cells and endothelial cells. 
 All of these inhibitors could be key in manipulating in-
tracellular pH and therefore the multi-drug resistance pheno-
type. 
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